8-K: Propanc Biopharma Secures Dilutive Private Placement

Propanc Biopharma, Inc. entered into a Securities Purchase Agreement with Hexstone Capital LLC for a private placement of Series C Preferred Stock and Warrants to fund general corporate purposes.

Summary

• Propanc Biopharma, Inc. (the "Company") entered into a Securities Purchase Agreement (SPA) with Hexstone Capital LLC ("Hexstone") on October 7, 2025.
• The agreement involves a private placement of a newly created class of Series C Preferred Stock and a Warrant to purchase additional Series C Preferred Stock.
• Each share of Series C Preferred Stock is convertible into common stock at a price equal to the lesser of a fixed conversion price of $5.00 per share or 85% of the lowest trading price of the Common Stock during a specified period.
• At the closing, the Company will issue 100 shares of Series C Preferred Stock and a Warrant to purchase up to an additional 9,900 shares of Series C Preferred Stock.
• The Warrants are exercisable at an exercise price of $10,000 per Warrant Share.
• Proceeds from the sale of the securities are designated for general corporate purposes, explicitly excluding the satisfaction of indebtedness (with exceptions), redemption/repurchase of securities, or settlement of outstanding litigation (with exceptions).
• The Company is required to obtain stockholder approval for the issuance of the securities, either through a special meeting within 90 days of the Closing Date or written consent within 45 days.
• The Company will reimburse Hexstone Capital LLC for transaction expenses up to a maximum of $50,000, with $15,000 already paid.
• A penalty of $100,000 is payable to the Buyer if the Company terminates the agreement prior to the closing.
• The Company has a 'Call Option' to purchase up to 500 Warrants per calendar month at $0.01 each, subject to certain conditions and the Buyer's right to exercise prior to the call's effective date.
• Each Buyer's sales of Common Stock are limited to the greater of $50,000 per Trading Day or 20% of the average daily trading volume per calendar month.

Sentiment

Score: 5

Explanation: While securing capital is positive for a biopharma company, the highly dilutive nature of the convertible preferred stock with a variable conversion price (85% of lowest trading price) and the significant potential for future share issuance from the warrants could substantially impact existing shareholder value. The restrictions on future financing also limit flexibility. The call option on warrants offers some mitigation but overall, the terms appear heavily skewed towards the investor, leading to a neutral to slightly negative sentiment for existing common shareholders.

Positives

• Secures capital for general corporate purposes, which can support ongoing operations and strategic initiatives.
• The establishment of a new class of convertible preferred stock (Series C) provides a structured financing mechanism.
• The Company retains a 'Call Option' to repurchase Warrants, offering a mechanism to manage potential future dilution or capital structure.

Negatives

• The conversion price mechanism (lesser of $5.00 or 85% of the lowest trading price) can lead to substantial dilution for existing common stockholders if the stock price declines.
• The issuance of 100 shares of Series C Preferred Stock and Warrants for 9,900 additional shares represents significant potential future dilution.
• The Company is restricted from issuing certain other equity or equity-linked securities (Variable Rate Transactions) during a 'Restricted Period' without prior written consent, limiting future financing flexibility.
• The requirement for stockholder approval introduces a contingency and potential delay in fully executing the transaction.
• A $100,000 penalty is imposed on the Company if it terminates the agreement prior to closing, indicating a strong commitment to the transaction.
• The Company explicitly acknowledges that the issuance of the Securities may result in substantial dilution of the outstanding shares of Common Stock.

Risks

• Dilution Risk: The variable conversion price (85% of the lowest trading price) of the Series C Preferred Stock and the potential exercise of Warrants pose a significant risk of substantial dilution to existing common stockholders.
• Stockholder Approval Risk: Failure to obtain timely stockholder approval for the issuance of securities could delay or complicate the transaction, potentially impacting the Company's ability to secure the intended funding.
• Market Price Volatility: The conversion price's dependence on the lowest trading price means a declining stock price could lead to a greater number of common shares being issued upon conversion, exacerbating dilution.
• Financing Flexibility Restrictions: Covenants restrict the Company from engaging in certain 'Variable Rate Transactions' or issuing other equity/equity-linked securities during a 'Restricted Period' without investor consent, potentially limiting future capital raising options.
• Liquidity Risk: The 'leak-out' provision, limiting the Buyer's daily sales volume, could impact the Buyer's ability to monetize their investment quickly and potentially affect market dynamics if the Buyer needs to sell a large volume of shares.
• Legal and Regulatory Compliance: The Company must comply with various SEC and Principal Market rules, including timely filings and maintaining listing, with potential delisting risks if not met.
• Insolvency Risk: While the Company represents it is not Insolvent and will not be after the transaction, this is a standard representation, and the filing does not provide detailed financial health information to independently assess this risk.

Future Outlook

The Company intends to use the proceeds from this private placement for general corporate purposes, aiming to support ongoing operations and strategic initiatives. It also commits to maintaining its listing on the Principal Market and ensuring sufficient authorized shares for future conversions, indicating a focus on long-term capital structure management and market presence. The Company will also seek stockholder approval for the issuance of the securities.

Management Comments

• The Company acknowledges and agrees that each Buyer is acting solely in the capacity of an arms length purchaser with respect to the Transaction Documents.
• The Company acknowledges that its obligations under the Transaction Documents, including, without limitation, its obligation to issue the Conversion Shares pursuant to the Transaction Documents, are unconditional and absolute and not subject to any right of set off, counterclaim, delay or reduction, regardless of the effect of any such dilution or any claim the Company may have against any Buyer and regardless of the dilutive effect that such issuance may have on the ownership of the other stockholders of the Company.
• The Company understands and acknowledges that the issuance of the Securities may result in dilution of the outstanding shares of Common Stock, which dilution may be substantial under certain market conditions, and that the number of Conversion Shares may increase in certain circumstances.
• The Company acknowledges that such aforementioned hedging and/or trading activities do not constitute a breach of this Agreement, the Certificate of Designations, or any other Transaction Document or any of the documents executed in connection herewith or therewith.

Industry Context

This private placement is a common financing strategy for biopharma companies, particularly those in development stages, to secure capital for research, clinical trials, or general operations without immediate public market pressure. The use of convertible preferred stock and warrants allows the company to defer immediate equity dilution while offering investors potential upside. The terms, including variable conversion prices, reflect the risk-reward profile often seen in early to mid-stage biopharma investments, where access to capital is critical for advancing drug candidates.

Comparison to Industry Standards

• The use of convertible preferred stock with warrants is a standard financing instrument in the biotechnology and pharmaceutical sectors, often employed by companies seeking growth capital while managing immediate common stock dilution.
• The variable conversion price, set at the lesser of a fixed price or a discount to market price (85% of lowest trading price), is a common feature in structured equity financings, sometimes referred to as 'death spiral' financing, which can be highly dilutive to existing shareholders if the stock price declines. This contrasts with more traditional fixed-price conversions or market-based conversions without a significant discount, which are often seen in more mature companies or less risky ventures.
• The 'leak-out' provision, limiting the buyer's daily sales volume, is a common protective measure in such agreements to prevent excessive selling pressure on the stock, although the specific thresholds ($50,000 or 20% of ADTV) vary by deal size and company liquidity. For a small-cap biopharma, these limits might still represent a significant portion of daily trading volume.
• The requirement for stockholder approval for the issuance of securities is a standard corporate governance practice, particularly when the issuance could exceed certain thresholds or significantly alter the capital structure, aligning with Nasdaq listing rules. The inclusion of a voting agreement from officers and directors is a common mechanism to ensure such approvals in these types of transactions.

Corporate Governance

Stakeholder Impact

• Shareholders: Existing common stockholders face significant potential for dilution due to the variable conversion price of the Series C Preferred Stock and the issuance of warrants. The 'leak-out' provision aims to mitigate immediate selling pressure, but long-term dilution remains a primary concern.
• Investors (Hexstone Capital LLC): Gains a significant equity position with favorable conversion terms and downside protection, along with a call option on warrants, positioning them advantageously in the Company's capital structure.
• Management/Board: Committed to a voting agreement to support the transaction, aligning their votes with the investor's interests for certain approvals, which could impact their autonomy in future corporate decisions.
• Creditors: The capital raise for general corporate purposes could improve the Company's financial stability, potentially benefiting creditors by strengthening the balance sheet, though the dilutive nature of the equity raise might not directly impact debt holders unless it significantly alters the Company's ability to service debt.

Next Steps

• File a Certificate of Designation of the Series C Preferred Stock with the Delaware Secretary of State.
• Hold a special meeting of stockholders (or obtain written consent) within 90 days (or 45 days for written consent) of the Closing Date to obtain Stockholder Approval for the issuance of securities.
• File a Current Report on Form 8-K describing the material terms of the transactions within two business days following the Closing Date.
• Maintain listing of all securities on the Principal Market.
• Timely file all reports with the SEC pursuant to the 1934 Act.
• Ensure sufficient authorized and reserved shares of common stock for conversion of Series C Preferred Stock.

Key Dates

Recommendation

While the capital raise provides necessary funding for general corporate purposes, the highly dilutive terms of the Series C Preferred Stock, particularly the variable conversion price (85% of the lowest trading price), present a significant risk to existing common shareholders. The potential for substantial dilution and restrictions on future financing flexibility warrant caution. Investors should hold and monitor the company's use of proceeds, progress on corporate objectives, and the impact of future conversions on the common stock price before making further investment decisions. The terms appear heavily weighted in favor of the investor, suggesting a challenging financing environment for the Company.

Keywords

Propanc Biopharma, PPCB, SEC Filing, 8-K, Private Placement, Series C Preferred Stock, Warrants, Convertible Securities, Dilution, Capital Raise, Hexstone Capital LLC, Equity Financing, Corporate Governance, Nasdaq